RTTNews | Dec 11, 2021 12:55PM EST

12:55 Saturday, December 11, 2021 (RTTNews.com) - Regeneron Pharmaceuticals Inc. (REGN) said that results from the Phase 1 portion of the Phase 1/2 trial in patients with relapsed/refractory multiple myeloma found a 51% overall response rate across all dose groups, rising to 75% in patients who received higher doses of REGN5458 (200-800 mg).

REGN5458 is a bispecific antibody designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells. It is currently being assessed in the potentially registrational Phase 2 portion of the trial, which is expected to complete recruitment in 2022.

Among patients who responded across all dose groups (3-800 mg), there was a 90% probability of being event-free (i.e., alive without disease progression) 8 months from the time of response, the company said.

Read the original article on RTTNews ( https://www.rttnews.com/3248599/regeneron-regn5458-phase-1-data-show-75-response-rate-at-highest-dose-levels-in-multiple-myeloma.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved